Siponimod

Drug Profile

Siponimod

Alternative Names: BAF-312

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Novartis
  • Class
  • Mechanism of Action Immunosuppressants; Sphingosine 1 phosphate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple sclerosis
  • Phase II Dermatomyositis; Polymyositis
  • Phase I Liver failure; Renal failure

Most Recent Events

  • 17 Sep 2016 Adverse events and efficacy data from the phase III EXPAND trial in Multiple sclerosis presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2016)
  • 01 Aug 2016 Novartis Pharmaceuticals completes a phase II trial in Polymyositis in USA, Belgium, Czech Republic, Hungary, Taiwan, Canada and Poland (NCT01801917)
  • 21 Apr 2016 Novartis completes a phase I trial in Healthy volunteers in USA, Switzerland, Jordan, Australia and France (PO) (CTP 233892)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top